Project Grant R01HL170945
Award Date
7/15/24
Completion Date
4/30/28
Dollars Obligated
$3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Tyler, TX 75708, USA
Similar Awards
This $151,523 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research by The Medical College of Wisconsin, Inc. to investigate the role of the protein fibrinogen in regulating inflammatory and clotting processes associated with acute and chronic venous thrombosis (blood clots). The research will utilize novel RNA therapy delivered via lipid nanoparticles to selectively reduce...
This federal Project Grant award of $930,481 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of North Texas. The funding supports a 3-year research project focused on synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesis, which are critical processes for platelet production. The project aims to determine the interaction between a specific...
This federal Project Grant award of $198,720 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to understand the impact of invasive mechanical ventilation on functional fibrinolysis and thromboinflammation in critically ill children. The primary objectives are to determine how ventilation intensity affects fibrinolysis, identify plasma biomarkers of venous thromboembolism (VTE) risk, and develop an...
This federal Project Grant award of $2,180,494 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to improve diagnostic and therapeutic strategies for pulmonary embolism (PE). The primary awardee, Masonic Medical Research Lab, will utilize a novel murine model of PE to investigate the inflammatory and fibrotic response to emboli of varying age and size. The project will employ longitudinal molecular...
This federal Project Grant award of $395,314 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the innate immune cell profile and cytokine microenvironment that mediate the development of inhibitory antibodies against factor VIII in individuals with hemophilia A. The research aims to 1) examine the cytokine profile and activation of conventional dendritic cells (CDC2) that drive CD4+ T cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $666,710 to The Johns Hopkins University to conduct research on the role of the BCL6 co-repressor (BCOR) in regulating coagulation factor VII and its impact on venous thromboembolism (VTE) risk. The key objectives are to: (1) characterize how BCOR suppresses factor VII expression through epigenetic regulators PRC1.1 and ATAC,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $685,884 to the University of North Carolina at Chapel Hill to conduct research on the regulation of coagulation and thrombosis by C1 inhibitor. The research aims to elucidate the molecular mechanisms by which endogenous C1 inhibitor regulates coagulation and venous thrombosis, evaluate the impact of C1 inhibitor deficiency on coagulation...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research into the molecular mechanisms underlying heart failure in patients with single ventricle congenital heart disease (CVD). The $655,636 award to the Texas Heart Institute, which runs from January 1, 2025 to November 30, 2028, will investigate the role of cardiac fibroblast senescence and metabolic remodeling in...
The University of Massachusetts (UMass) was awarded a $601,677 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund a multi-scale research study to characterize the molecular mechanisms underlying vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but dangerous side effect observed with adenoviral-vectored COVID-19 vaccines. The research team, comprising experts in...
This $674,338 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the genetic architecture regulating tissue factor (TF) expression and its impact on human bleeding and thrombotic risk. The project aims to: 1) Evaluate new transcriptional activators and repressors of the F3 promoter that controls TF expression across human tissues, and identify rare human genetic...